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Even when the US Food and Drug Administration approved erythropoietin to treat chemotherapy-induced anemia in 1993, concern was raised that administration of erythropoietin may lead to tumor growth. This possibility was derived from concern that erythropoietin receptors or homologous receptors reside on cancer cells and respond to exogenous erythropoietin, inducing activation of the cell signaling pathway and cellular functional changes. There has been widespread disagreement on this topic. Before 2008, a review found that scientists without funding from manufacturers of erythropoiesis-stimulating agents (ESAs) were more likely than scientists with such funding or scientists employed by manufacturers of ESAs to report erythropoietin receptors on solid tumor cells, erythropoietin-induced signaling changes, or cellular function changes. 1 Three studies have been published by scientists employed by manufacturers of ESAs, which was too small a number to allow for direct comparisons between findings of academic scientists and scientists employed by manufacturers of ESAs. 1 In 2007, the National Cancer Institute convened a workshop seeking to facilitate consensus on this topic. Thirteen of 14 academic scientists without funding from manufacturers of ESAs reported that erythropoietin receptors were involved in cancer progression while all 6 scientists employed by manufacturers of ESAs reported the opposite (A. Mufson, PhD, written communication, August 2015) (Table) . Review of subsequent studies provides opportunities to evaluate whether consensus was achieved after the workshop. Our hypothesis is that differences in findings regarding erythropoietin receptors between academic scientists and scientists employed by manufacturers of ESAs would persist after the workshop. Receptors other than EpoRs were amplified EpoR was detected on head and neck squamous cell carcinoma cell lines; higher EpoR mRNA levels detected in head and neck cancer specimens and in lymph node metastases vs adjacent tissues.
Methods

EpoR ubiquitously expressed but not elevated in tumor tissues
Low-level EpoR expression was seen in nevi and melanoma cell lines. Melanoma cells stained positive for EpoR expression; benign moles did not. Hypoxia stimulated Epo and blocked autocrine Epo production effects by melanoma cells via apoptosis.
Human endothelial cells exhibited low EpoR mRNA levels and no detectable surface EpoR or Epo binding
EpoR mRNA was detected on cell lines for breast and prostate cancer but less so in positive controls
Epo-Induced Signaling Events
Cyclin D1 expression was increased 10-fold in breast cancer cell lines
In melanoma cell lines, Epo activated Janus kinase-2 and protein kinase B (Akt) pathways.
Extracellular signal-regulated kinase-1/2 (ERK1/2) markers increased in ovarian cancer A2780 cells after 4 days of Epo treatment.
In head and neck squamous cell carcinoma cell lines, Epo activated Janus kinase-2-STAT5 signaling.
Epo induced protein kinase beta (Akt) signaling and increased expression in an orthotopic mouse window model that had been injected with R230 rat mammary adenocarcinomas, CT-26 mouse colon carcinoma, HCT-116 human colon carcinoma, and FaDu human head and neck squamous cell carcinoma (each cell line expresses EpoR).
Epo-Induced Cellular Functional Changes
No detectable proliferative advantage to EpoR overexpression
Long-term Epo treatment of A2780 cells resulted in paclitaxel resistance. Nude mice studies showed that inhibiting EpoR expression in ovarian cancer cell xenografts decreased cell growth and invasiveness.
3-Fold increases were found in cell numbers in AR42J murine pancreatic cancer cells with Epo treatment. 13-Week Epo treatment of mice xenografts resulted in increased recurrence of tumors; with EpoR knockdowns, the cells grew slower in vitro.
Epo did not stimulate rat endothelial cells growth or angiogenesis
After EpoR transfection to Chinese hamster ovary K1 cells, cell proliferation occurred that was proportional to EpoR levels in cells.
Using dorsal mammary windows from an orthotopic mammary model, Epo injection into rat tumors resulted in 66% increased tumor growth and 78% increased vascular growth.
No deleterious effects of ESA administration for 2 weeks on in vivo rat tumor volume MCF-7 breast cancer cells showed a lack of Epo influence on suppression of paclitaxel-or doxorubicin-induced apoptosis.
Epo stimulation of head and neck squamous cell carcinoma cells increased proliferation and invasion.
No deleterious effect of ESA administration on paclitaxel efficacy in xenografts using breast cancer cell lines Epo did not influence cytarabine or doxorubicin toxicity in erythroleukemia cells.
Abbreviations: Epo, erythropoietin; EpoR, erythropoietin receptors; ESA, erythropoeisis-stimulating agent; mRNA, messenger RNA; STAT5, signal transducer and activator of transduction 5. a These studies were conducted in multiple cell lines from multiple types of cancer.
b These studies were conducted in cell lines from single types of cancer.
Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma
Sentinel lymph node (SLN) mapping is an integral part of the staging of cutaneous malignant melanoma. If regional metastases are identified on SLN biopsy, patients undergo completion lymph node dissection (LND) with curative intent. Microscopic regional lymph node involvement, however, is a strong predictor of disease-specific survival and delineates a population at high risk of developing metastatic melanoma. 1 The National Comprehensive Cancer Network (NCCN) makes a category 2B recommendation based on low-level evidence for staging by positron emission tomography coupled with computed tomography (PET/CT) prior to LND. 2 Discovery of occult synchronous metastases informs prognosis, may preclude LND, and presents an opportunity for metastasectomy, which can improve survival in patients with low-volume stage IV disease. 3 Existing data suggests that PET/CT has use in the detection of metastases from multiple primary tumor types. 4 However, PET/CT lacks data supporting its use in staging asymptomatic patients with early-stage melanoma, may inconsistently impact treatment decisions, and carries a false-positive finding risk that may detract from its use. To evaluate an evolving practice, this study aims to assess the use of PET/CT in detecting occult metastases in SLN-positive melanoma.
Methods | A retrospective evaluation of patients with melanoma and clinically silent regional lymph nodes treated at the University of Michigan between April 2013 and September 2014 was performed. Patients with palpable lymph nodes or symptoms of metastatic disease were excluded. We identified 78 patients with positive SLN mapping, 46 of whom underwent PET/CT prior to LND. Remaining patients either underwent no staging or body computed tomography with brain magnetic resonance imaging as ordered by the referring physician. Relevant clinical data were obtained from the medical record ( Table 1) . Accuracy of PET/CT findings was assessed accord- 
